Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Bionor Pharma ASA - Key information relating to the conditional Subsequent Offering

Bionor Pharma ASA
Posted on: 24 Nov 16

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANYOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Bionor Pharma ASA - Key information relating to the conditional Subsequent Offering

Oslo, 24 November 2016

Reference is made to Bionor Pharma ASA's ("Bionor" or the "Company") announcement regarding a successfully completed Private Placement and a contemplated fully underwritten Subsequent Offering published earlier today. The Private Placement and Subsequent Offering are conditional upon approval by the shareholders in an extraordinary general meeting (the "EGM") to be held on 14 December 2016.

The Board has proposed to conduct a Subsequent Offering to existing shareholders who were not allocated shares in the Private Placement nor participated in the underwriting consortium, provided that such shareholders are not resident in a jurisdiction where such offering would be unlawful, or would (in jurisdictions other than Norway) require any prospectus filing, registration or similar action. The Subsequent Offering is inter alia subject to approval by the EGM, completion of the Company's acquisition of Solon Eiendom AS and the Private Placement and a prospectus being approved by the Norwegian Financial Supervisory Authority and published by the Company.

Key information in relation to the conditional subsequent offering:

Date on which the terms and conditions of the rights offering were announced 21 November 2016
Last day including right 23 November 2016
Ex-date 24 November 2016
Record date 25 November 2016
Date of approval 14 December 2016
Maximum number of new shares in the subsequent offering 666,666,666 new shares
Subscription price NOK 0.15 per share
Shall the rights be listed yes/no Yes

This information is published in accordance with the requirements of the Continuing Obligations.

Bionor_SEA20161124_KeyInfoSubsequentOffering


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Bionor Pharma ASA via GlobeNewswire
HUG#2059030
GlobeNewswire
globenewswire.com

Last updated on: 25/11/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.